- About Us
- CARDI Grants Programme
- Research database and directory
- Useful Links
Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty
Date published:26 August, 2008
Title: Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial
The most effective magnitude and timing of antiplatelet therapy is important in patients with acute ST-elevation myocardial infarction (STEMI). We investigated whether the results of primary coronary angioplasty (PCI) can be improved by the early administration of the glycoprotein IIb/IIIa blocker tirofiban at first medical contact in the ambulance or referral centre.
We undertook a double-blind, randomised, placebo-controlled trial in 24 centres in the Netherlands, Germany, and Belgium. Between June 29, 2006, and Nov 13, 2007, 984 patients with STEMI who were candidates to undergo PCI were randomly assigned to either high-bolus dose tirofiban (n=491) or placebo (N=493) in addition to aspirin (500 mg), heparin (5000 IU), and clopidogrel (600 mg). Randomisation was by blinded sealed kits with study drug, in blocks of four. The primary endpoint was the extent of residual ST-segment deviation 1 h after PCI. Analysis was by intention to treat. The trial is registered, number ISRCTN06195297.
936 (95%) patients were randomly assigned to treatment after a prehospital diagnosis of myocardial infarction in the ambulance. Median time from onset of symptoms to diagnosis was 76 min (IQR 35–150). Mean residual ST deviation before PCI (10·9 mm [SD 9·2] vs 12·1 mm [9·4], p=0·028) and 1 h after PCI (3·6 mm [4·6] vs 4·8 mm [6·3], p=0·003) was significantly lower in patients pretreated with high-bolus dose tirofiban than in those assigned to placebo. The rate of major bleeding did not differ significantly between the two groups (19 [4%] vs 14 [3%]; p=0·36).
Our finding that routine prehospital initiation of high-bolus dose tirofiban improved ST-segment resolution and clinical outcome after PCI, emphasises that further platelet aggregation inhibition besides high-dose clopidogrel is mandated in patients with STEMI undergoing PCI.
- Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, trial
- Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
- PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab...
- The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
- Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease
- Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study
- Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer
- Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study
- Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein...